Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis
- PMID: 39892787
- DOI: 10.1016/j.clnesp.2025.01.056
Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis
Abstract
Background & aims: Semaglutide has demonstrated efficacy in both glycemic control and weight loss. This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals diagnosed with type 2 diabetes mellitus (T2DM).
Methods: PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), and China Science and Technology Journal Database (VIP) were searched to identify relevant publications. The primary outcome measure was the change in HbA1c levels. Secondary outcome measures encompassed change in body weight, fluctuations in FPG levels, occurrence of adverse events, serious adverse events, hypoglycemic episodes, and gastrointestinal reactions including nausea, vomiting, and diarrhea. Mean differences (MDs) and relative risk (RR) with confidence intervals (CI) of 95 % were used to analyze the deference.
Results: 7 RCTs with 2354 patients were incorporated into the study. Compared to placebo or other active treatment, the addition of semaglutide to basal insulin demonstrated significant reductions in hemoglobin A1c (HbA1c) [mean differences (MD): -1.17 %, P < 0.00001], body weight [MD -5.99 kg, P < 0.00001], and fasting blood glucose (FPG) [MD -1.08 %, P < 0.00001]. No evidence indicated a higher risk of adverse events [RR 1.46, P = 0.13]. However, it did result in increased rates of gastrointestinal adverse events, including nausea, vomiting and diarrhea.
Conclusions: The combination treatment of semaglutide and basal insulin demonstrates significant improvements in glycemic control and reduction in body weight, without an increased risk of hypoglycemia. Our findings provided support for the utilization of a combination therapy involving semaglutide and basal insulin in T2DM.
Keywords: Glucagon-like peptide-1 receptor agonists; HbA1c; Insulin; Semaglutide; Type 2 diabetes mellitus.
Copyright © 2025. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest The authors declare no competing interests.
Similar articles
-
Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.J Clin Pharmacol. 2024 Oct;64(10):1312-1325. doi: 10.1002/jcph.2483. Epub 2024 Jun 14. J Clin Pharmacol. 2024. PMID: 38874130
-
Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study.Diabetes Obes Metab. 2025 Jun;27(6):3084-3093. doi: 10.1111/dom.16314. Epub 2025 Mar 6. Diabetes Obes Metab. 2025. PMID: 40045764
-
The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.Endocrine. 2018 Dec;62(3):535-545. doi: 10.1007/s12020-018-1708-z. Epub 2018 Aug 12. Endocrine. 2018. PMID: 30101378
-
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.J Clin Endocrinol Metab. 2018 Jun 1;103(6):2291-2301. doi: 10.1210/jc.2018-00070. J Clin Endocrinol Metab. 2018. PMID: 29688502 Free PMC article. Clinical Trial.
-
Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.Diabetes Obes Metab. 2018 Sep;20(9):2255-2263. doi: 10.1111/dom.13361. Epub 2018 Jun 10. Diabetes Obes Metab. 2018. PMID: 29756388
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous